Prodrugs with Peptides as a Carrier for Cancer Treatment
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: closed (30 April 2022) | Viewed by 3300
Special Issue Editor
Interests: antimicrobial peptides; pathogenic bacteria; breast cancer; cancer-targeting agents; cancer diagnostics
Special Issue Information
Dear Colleagues,
Prodrugs with peptides as a carrier, also known as peptide–drug conjugates (PDCs), consist of a targeting peptide covalently conjugated to an anti-cancer drug via a linker. In a PDC, the peptide targets the conjugate to cancer cells sparing non-cancerous healthy cells and tissues. After reaching the cancer site, the linker is cleaved to release the drug that specifically kills the cancer cells. PDCs increase the efficacy and decrease the side effects of an anti-cancer drug by targeting the drug to the cancer site. PDCs have gained recognition in recent years for cancer therapy. Their success has been evident with the recent FDA approval of two PDCs. A PDC lutetium 177 DOTA-TATE, where radionuclide 177Lu is covalently linked to a somatostatin receptor targeting peptide (tyrosine-3 octreotate), was approved for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors in 2018. In addition, a PDC melphalan flufenamide that targets aminopeptidases was approved for the treatment of relapsed or refractory multiple myeloma in 2021. This Special Issue seeks research on “Prodrugs with Peptides as a Carrier for Cancer Treatment” to foster the development of PDCs for cancer treatment.
Prof. Dr. Kamaljit Kaur
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer cell targeting/homing peptide
- linker chemistry
- peptide–drug conjugate
- prodrug
- therapeutic efficacy
- targeted drug delivery
- targeted cancer therapy
